The reason why!
Yesterday I noted that the iLet by Beta Bionics has the opportunity to hurt both Tandem and Medtronic. The biggest reason isn’t because the iLet is easy to use no the biggest reason is Beta Bionics has done what Tandem and Medtronic have been unable or incapable of doing, the iLet will be available through the pharmacy channel and will not have to compete with the 780G or Control IQ via the more costly DME channel.
Besides Medtronic and Embecta reporting yesterday both noted they are getting ready to compete with Insulet in the patch pump space. Neither stands . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.